5 completed. 5 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 5 |
| Phase 2 | 3 | Completed 3 |
Follow SCLC: new trials by email Literature Review of SCLC trials Research Report on SCLC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors Berzosertib, Sacituzumab Govitecan - HRD Cancer, SCLC | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 35 | 2021-09-20 | 2026-07-21 |
| A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer Carboplatin, Cisplatin, Etoposide - SCLC | Phase 1 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 60 | 2021-09-07 | 2023-07-19 |
| A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Nivolumab, Plinabulin, Ipilimumab - Lung Cancer, SCLC | Phase 1 / Phase 2 | Completed | Salma Sabbour | 39 | 2018-09-06 | 2026-01-20 |
| Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors Lurbinectedin, Irinotecan - Advanced Solid Tumors, Glioblastoma | Phase 1 / Phase 2 | Completed | PharmaMar | 316 | 2016-05-06 | 2025-07-09 |
| BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors BB-10901 - Ovarian Cancer, Merkel Cell Carcinoma | Phase 1 | Completed | ImmunoGen, Inc. | 97 | 2002-03-01 | 2015-03-26 |
Carcinoma, Merkel Cell (1) · Carcinoma, Ovarian Epithelial (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Gastro-enteropancreatic neuroendocrine tumor (1) · Glioblastoma (1) · Lung Neoplasms (1) · Mesothelioma (1) · Neoplasms (1) · Neuroendocrine Tumors (1) · Ovarian Neoplasms (1) · Sarcoma (1) · Small Cell Lung Carcinoma (1) · Stomach Neoplasms (1)
Neoplasms by Site (3) · Adnexal Diseases (2) · Carcinoma (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genital Diseases (2) · Genital Diseases, Female (2) · Genital Neoplasms, Female (2) · Gonadal Disorders (2) · Lung Diseases (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Germ Cell and Embryonal (2)
Carboplatin (1) · Cisplatin (1) · Etoposide (1) · Ipilimumab (1) · Irinotecan (1) · NPI 2358 (1) · Nivolumab (1) · PM 01183 (1) · berzosertib (1) · lorvotuzumab mertansine (1) · sacituzumab govitecan (1) · sintilimab (1)
ImmunoGen, Inc. (1) · Innovent Biologics (Suzhou) Co. Ltd. (1) · National Cancer Institute (NCI) (1) · PharmaMar (1) · Salma Sabbour (1)
United States (4) · China (1) · France (1) · Germany (1) · Italy (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Anish Thomas, M.D. (1) · Paul C. Lorigan, MD (1) · Salma Jabbour, MD (1)